We are live on ! Find out more

2,813 hedge funds and large institutions have $90.5B invested in Pfizer in 2025 Q2 according to their latest regulatory filings, with 140 funds opening new positions, 1,177 increasing their positions, 1,237 reducing their positions, and 229 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.63% less ownership

Funds ownership: 66.27%65.64% (-0.63%)

5% less repeat investments, than reductions

Existing positions increased: 1,177 | Existing positions reduced: 1,237

5% less capital invested

Capital invested by funds: $95.2B → $90.5B (-$4.69B)

4% less funds holding

Funds holding: 2,9362,813 (-123)

21% less call options, than puts

Call options by funds: $2.61B | Put options by funds: $3.32B

34% less funds holding in top 10

Funds holding in top 10: 4429 (-15)

39% less first-time investments, than exits

New positions opened: 140 | Existing positions closed: 229

Holders
2,813
Holders Change
-123
Holders Change %
-4.19%
% of All Funds
36.95%
Holding in Top 10
29
Holding in Top 10 Change
-15
Holding in Top 10 Change %
-34.09%
% of All Funds
0.38%
New
140
Increased
1,177
Reduced
1,237
Closed
229
Calls
$2.61B
Puts
$3.32B
Net Calls
-$713M
Net Calls Change
+$183M

PFE Hedge Fund Activity: Q2 2025 in Review

2,813 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2025, worth a combined $90.5B — down 4.9% from $95.2B a quarter earlier.

Sellers outnumbered buyers: 229 funds closed out of PFE and 140 opened new positions — a net loss of 89 holders — while 1,237 trimmed existing stakes and 1,177 added.

The largest buyer was BlackRock, adding an estimated $483M. The largest seller was Wellington Management Group, cutting an estimated $618M.

  • 2,813 institutional investors held Pfizer (PFE) as of Q2 2025, down from 2,936 in Q1 2025.
  • Funds reported $90.5B of Pfizer stock for Q2 2025, down 4.9% quarter-over-quarter.
  • 140 funds opened new Pfizer positions in Q2 2025 and 229 closed out, a net change of -89 holders.
  • The largest Pfizer buyer in Q2 2025 was BlackRock, an estimated $483M added.
  • The largest Pfizer seller in Q2 2025 was Wellington Management Group, an estimated $618M sold.

Based on aggregated 13F filings for Q2 2025.